River Global Investors LLP Has $494,000 Stock Holdings in Organon & Co. (NYSE:OGN)

River Global Investors LLP decreased its stake in Organon & Co. (NYSE:OGN - Free Report) by 43.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,084 shares of the company's stock after selling 25,691 shares during the period. River Global Investors LLP's holdings in Organon & Co. were worth $494,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Prospera Private Wealth LLC acquired a new stake in Organon & Co. in the 3rd quarter worth $25,000. Horizon Bancorp Inc. IN lifted its stake in shares of Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock valued at $25,000 after buying an additional 1,585 shares during the period. Riverview Trust Co grew its position in Organon & Co. by 117.7% during the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after buying an additional 1,292 shares in the last quarter. Versant Capital Management Inc increased its stake in Organon & Co. by 92.2% during the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company's stock valued at $41,000 after acquiring an additional 1,324 shares during the period. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock valued at $41,000 after acquiring an additional 672 shares in the last quarter. Institutional investors own 77.43% of the company's stock.

Remove Ads

Analyst Ratings Changes

OGN has been the topic of several recent research reports. TD Cowen raised Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Barclays decreased their price target on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Finally, Morgan Stanley dropped their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $20.80.

Organon & Co. Price Performance

OGN stock traded down $0.58 during trading on Wednesday, hitting $15.03. The company had a trading volume of 3,543,762 shares, compared to its average volume of 2,337,523. The company has a fifty day moving average price of $15.46 and a two-hundred day moving average price of $16.80. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The company has a market cap of $3.88 billion, a P/E ratio of 4.51, a P/E/G ratio of 0.90 and a beta of 0.76. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Equities research analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.45%. The ex-dividend date is Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is currently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.